Grey Wolf Therapeutics will present an e-poster and accompanying audio description at AACR 2020 (Virtual Annual Meeting II).

The company has generated potent oral ERAP1 inhibitors that modify the immunopeptidome in vivo and represent novel immunotherapy agents.

Visit the American Association for Cancer Research website and head to e-poster 5551 for more information. The virtual event will run from June 22 – June 24.

You can request a copy of the poster by clicking here.